Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III

  • News

Executive Summary

Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.

You may also be interested in...



Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps

Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January

Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps

Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January

Organon Arixtra Anti-Thrombotic Could Clear FDA By Mid-August

Organon's anti-thrombotic agent Arixtra could receive approval from FDA in mid-August, Organon President Hans Vemer told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.

Table

View full table

Related Content

Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By